我国妇产科药学监护案例的质量评估及分析

目的 通过案例报道评估工具(case repert guideline,CARE)对国内妇产科药学监护案例进行分析,为进一步建立妇产科临床药学案例分析评估体系提出依据及参考。方法 课题由2名临床药师通过关键词对中国知网及万方数据库进行检索,通过双人纳排、专家仲裁,对纳入案例进行筛选,根据CARE案例分析工具对纳入的国内妇产科药学监护案例进行评估,分别针对产科及妇科相关的病种、年份、论文类型进行分析,评估目前妇产科药学监护案例水平。结果 通过双人检索及筛选,上级临床药师审核,最终纳入产科药学监护案例65篇,妇科药学监护案例58篇。产科总体评估平均分(25.31±2.77),妇科总体评估平均分(24.66±3.29)。产科2016~2020年发表的药学监护案例CARE评分较2010~2015年显著(26.03±1.48)vs (24.41±3.64)],P＜0.05。妇科相关药学监护案例中期刊论文评估总平均分(25.13±1.97)质量总体优于会议论文评估总平均分(22.83±5.95),且P＜0.05。产科及妇科相关案例中,关于随诊、患者角度的治疗评估以及知情同意三项评分较低。结论 基于CARE能够有效针对妇产科药学监护案例进行分析,为进一步提高临床药师培训的教学质量提供借鉴及参考。

Analysis of Pharmaceutical Care Cases of Obstetrics and Gynecology in China

OBJECTIVE To analyze the pharmaceutical care cases of obstetrics and gynecology in China with Case Report guideline(CARE guideline), providing reference for establishing the evaluation system of clinical pharmaceutical cases in obstetrics and gynecology. METHODS Two clinical pharmacists searched the CNKI and Wanfang databases with keywords, and included the cases through double check and expert decision. With CARE guideline, the characteristics such as the diseases, published year, and article types, evaluating the quality of pharmaceutical care cases of obstetrics and gynecology were analyzed. RESULTS Through search and screening of two researchers, 65 cases of obstetrics and 58 cases of gynecology were included. The case scores were (25.31±2.77) of obstetrics and (24.66±3.29) of gynecology. Compared with 2010-2015, the CARE scores of obstetrics cases published in 2016-2020 were significantly improved(26.03±1.48) vs (24.41±3.64), P<0.05]. The paper quality of the journal(25.13±1.97) was better than the conference papers(22.83±5.95), P<0.05. In obstetrics and gynecology cases, the scores were low on follow-up, treatment evaluation from the perspective of patients and informed consent. CONCLUSION With CARE guideline, we can effectively analyze the pharmaceutical care cases of obstetrics and gynecology, and provide reference for improving the quality of clinical pharmacist training.